SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (893)11/5/2001 11:23:55 AM
From: tuck  Read Replies (1) of 1784
 
SIDT, can't tell if it's trickleish enough. Very busy still for another few days.

I believe BDAL reports today or soon. The media blitz begins . . .

>>SEQUENOM(TM), Inc. (Nasdaq: SQNM - news) and Bruker Daltonics Inc. (Nasdaq: BDAL - news) today announced an agreement to develop a next-generation bench-top mass spectrometer to be included in SEQUENOM'S MassARRAY(TM) genotyping system. Bruker Daltonics will develop the new GenoFlex for SEQUENOM based on the proven method of MALDI-TOF mass spectrometry, the same technology employed in SEQUENOM's existing high-throughput MassARRAY platform that also includes Bruker instrumentation. SEQUENOM will offer the GenoFlex system as a medium throughput (MT) model to expand the Company's genotyping market coverage over a broader range of potential customers.

``This agreement is a result of the strong working relationship we enjoy with Bruker Daltonics,'' said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. ``Our existing MassARRAY customers have come to rely on the quality instrumentation provided by Bruker Daltonics. The GenoFlex MT or medium throughput instrument is expected to build on the success of our MassARRAY system by providing the same reliable and accurate genotyping results provided by our high throughput product offering. We expect the addition of the GenoFlex MT to provide SEQUENOM with access to a broader market segment of customers which may be in the earlier stages of their ramp up in throughput requirements for genotyping, but are still interested in the features of our MassARRAY product line.''

Frank Laukien, Ph.D., President and CEO of Bruker Daltonics, commented, ``We are very impressed with SEQUENOM's success in establishing genotyping by MALDI-TOF mass spectrometry as a direct, highly accurate and high-throughput standard method, particularly for human pharmacogenomics and research in molecular diagnostics. Therefore, we are very pleased to expand our long-standing collaboration with SEQUENOM to the medium-throughput genotyping market.''<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext